Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience.
10.4111/kju.2010.51.7.450
- Author:
Eugene HWANG
1
;
Hyo Jin LEE
;
Chong Koo SUL
;
Jae Sung LIM
Author Information
1. Department of Urology, Chungnam National University School of Medicine, Daejeon, Korea. uro17@cnu.ac.kr
- Publication Type:Original Article
- Keywords:
Neoplasm metastasis;
Renal cell carcinoma;
Sunitinib
- MeSH:
Carcinoma, Renal Cell*;
Clinical Protocols;
Disease Progression;
Disease-Free Survival;
Edema;
Hand-Foot Syndrome;
Humans;
Incidence;
Neoplasm Metastasis;
Protein-Tyrosine Kinases;
Retrospective Studies
- From:Korean Journal of Urology
2010;51(7):450-455
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We assessed the efficacy and safety of the tyrosine kinase inhibitor sunitinib in Korean patients with metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS: Between September 2007 and December 2009, all twenty-one patients who had mRCC with a clear-cell component were retrospectively reviewed. Sunitinib was administered orally at a dose of 50 mg daily until disease progression or intolerance to treatment occurred. The primary end point of this study was the objective tumor response assessed by Response Evaluation Criteria in Solid Tumors (RECIST), and the secondary end points were progression-free survival (PFS) and overall survival (OS) rates as well as assessment of adverse effects. RESULTS: After a median of 17.4 months (range, 5.7-33.1 months) of treatment, 11 patients (52.4%) had an objective response with a complete response in 1 patient (4.8%), and a partial response in 10 patients (47.6%) as the best tumor response. The median PFS was 13.4 months (95% confidence interval [CI], range, 12.3-14.5 months), and the median OS was 28.1 months (95% CI, 21.8-34.4 months). All patients experienced adverse events of some sort, but the studied treatment protocol was well tolerated and most patients experienced reversible grade 1 or 2 toxicities. CONCLUSIONS: Sunitinib was efficacious in the treatment of metastatic clear-cell RCC, and was well tolerated in Korean patients. Although sunitinib treatment-related adverse events such as hand-foot syndrome and facial/generalized edema were observed with a higher incidence than in Western trials, they were mainly mild to moderate, and readily managed.
